Apogee Therapeutics, Inc.
US ˙ NasdaqGM ˙ US03770N1019

Introduction

This page provides a comprehensive analysis of the known insider trading history of Carl Dambkowski. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Carl Dambkowski has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:APGE / Apogee Therapeutics, Inc. Chief Medical Officer 233,548
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Carl Dambkowski. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases APGE / Apogee Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APGE / Apogee Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APGE / Apogee Therapeutics, Inc. Insider Trades
Insider Sales APGE / Apogee Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APGE / Apogee Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APGE / Apogee Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Carl Dambkowski as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-09-05 2025-09-03 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -190 233,548 -0.08 38.55 -7,324 9,003,275
2025-09-05 2025-09-03 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,535 233,738 -1.07 37.82 -95,874 8,839,971
2025-08-08 2025-08-06 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,725 236,273 -1.14 37.78 -102,950 8,926,394
2025-07-03 2025-07-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -746 238,998 -0.31 46.26 -34,510 11,056,047
2025-07-03 2025-07-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,935 239,744 -1.21 45.49 -133,513 10,905,955
2025-07-03 2025-07-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -6,409 242,679 -2.57 44.77 -286,931 10,864,739
2025-07-03 2025-07-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
M - Exercise 7,365 249,088 3.05 22.86 168,364 5,694,152
2025-06-06 2025-06-04 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,725 241,723 -1.11 36.96 -100,716 8,934,082
2025-05-09 2025-05-07 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,725 244,448 -1.10 35.75 -97,419 8,739,016
2025-04-04 2025-04-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -889 247,173 -0.36 37.59 -33,418 9,291,233
2025-04-04 2025-04-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -500 248,062 -0.20 37.03 -18,515 9,185,736
2025-04-04 2025-04-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,471 248,562 -0.98 35.56 -87,869 8,838,865
2025-03-07 2025-03-05 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -1,590 251,033 -0.63 30.48 -48,463 7,651,486
2025-02-07 2025-02-05 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -3,520 252,623 -1.37 40.69 -143,229 10,279,230
2025-02-07 2025-02-05 4 APGE Apogee Therapeutics, Inc.
Common Stock
M - Exercise 795 256,143 0.31 22.86 18,174 5,855,429
2025-01-03 2025-01-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -100 255,348 -0.04 47.92 -4,792 12,236,276
2025-01-03 2025-01-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,486 255,448 -0.96 47.21 -117,364 12,059,700
2025-01-03 2025-01-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -1,499 257,934 -0.58 46.42 -69,584 11,973,296
2025-01-03 2025-01-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
M - Exercise 1,360 259,433 0.53 22.86 31,090 5,930,638
2024-12-13 2024-12-11 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -455 258,073 -0.18 50.00 -22,750 12,903,650
2024-12-13 2024-12-11 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -4,085 258,528 -1.56 48.62 -198,613 12,569,631
2024-12-13 2024-12-11 4 APGE Apogee Therapeutics, Inc.
Common Stock
M - Exercise 1,815 262,613 0.70 22.86 41,491 6,003,333
2024-12-06 2024-12-04 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -6,665 260,798 -2.49 46.07 -307,057 12,014,964
2024-11-08 2024-11-06 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -1,339 267,463 -0.50 59.96 -80,286 16,037,081
2024-11-08 2024-11-06 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -5,326 268,802 -1.94 58.91 -313,755 15,835,126
2024-10-04 2024-10-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -925 274,128 -0.34 56.86 -52,596 15,586,918
2024-10-04 2024-10-02 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -5,740 275,053 -2.04 56.16 -322,358 15,446,976
2024-09-06 2024-09-04 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -787 280,793 -0.28 48.06 -37,823 13,494,912
2024-09-06 2024-09-04 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -5,878 281,580 -2.04 47.49 -279,146 13,372,234
2024-08-09 2024-08-07 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -670 287,458 -0.23 42.56 -28,515 12,234,212
2024-08-09 2024-08-07 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -142 288,128 -0.05 41.09 -5,835 11,839,180
2024-08-09 2024-08-07 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -6,523 288,270 -2.21 40.47 -263,986 11,666,287
2024-07-05 2024-07-03 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -2,143 294,793 -0.72 38.16 -81,777 11,249,301
2024-07-05 2024-07-03 4 APGE Apogee Therapeutics, Inc.
Common Stock
S - Sale X -3,852 296,936 -1.28 37.29 -143,641 11,072,743
2023-07-17 3/A APGE Apogee Therapeutics, Inc.
Common Stock
300,788
2023-07-13 3 APGE Apogee Therapeutics, Inc.
Common Stock
279,105
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)